The future of drug discovery is at Envisagenics

We use Artificial Intelligence and Machine Learning to unlock the therapeutic potential of RNA.

Our platform leverages RNA sequencing data and AI/ML algorithms to identify, test and validate drug targets with greater speed and precision than traditional methods.

Know more

Envisagenics’ SpliceCore^® software platform discovers novel targets to develop successful therapies

Traditional methods to detect RNA splicing variation have been limited – Envisagenics’ SpliceCore^® platform is able to scale the discovery of splicing-derived drug targets.

SpliceCore^® not only identifies new targets for RNA therapeutics but also explains the mechanism by which the antisense drugs regulate the splicing event, leading to more transparent and verifiable AI/ML predictions.

SpliceIO^TM, the immunotherapeutic branch of SpliceCore^®, identifies tumor specific neoepitopes targetable with a variety of antibody-based modalities.

SpliceCore^® Benchmarks

250x

larger search space for target discovery with SpliceCore’s exon-centric approach

78%

experimental validation rate for SpliceCore-discovered targets

100%

drug target candidates derived from disease-specific splicing events

View our pipeline

News

Oxford Global – Biologics Analysis – Insight Article – The Black Box Effect – How Can AI and ML Provide Transparent Insights for Drug Discovery?

August 30, 2022

Envisagenics is Awarded Another SBIR Grant From the National Cancer Institute to Commercialize its AI/ML Platform for Immunotherapy Development

August 3, 2022

Alliance for Artificial Intelligence in Healthcare Elects New Board Leadership for 2022

March 2, 2022

The future of drug discovery is at Envisagenics

Envisagenics’ SpliceCore^® software platform discovers novel targets to develop successful therapies

SpliceCore^® Benchmarks

News

Oxford Global – Biologics Analysis – Insight Article – The Black Box Effect – How Can AI and ML Provide Transparent Insights for Drug Discovery?

Envisagenics is Awarded Another SBIR Grant From the National Cancer Institute to Commercialize its AI/ML Platform for Immunotherapy Development

Alliance for Artificial Intelligence in Healthcare Elects New Board Leadership for 2022

Investors

Partners

Member

Foundations

The future of drug discovery is at Envisagenics

Envisagenics’ SpliceCore® software platform discovers novel targets to develop successful therapies

SpliceCore® Benchmarks

News

Investors

Partners

Member

Foundations

Envisagenics’ SpliceCore^® software platform discovers novel targets to develop successful therapies

SpliceCore^® Benchmarks